HUMA
Price
$1.09
Change
-$0.05 (-4.39%)
Updated
Jan 15, 04:59 PM (EDT)
Capitalization
220.02M
70 days until earnings call
Intraday BUY SELL Signals
NBTX
Price
$21.52
Change
-$0.01 (-0.05%)
Updated
Jan 15, 04:50 PM (EDT)
Capitalization
1.02B
103 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

HUMA vs NBTX

Header iconHUMA vs NBTX Comparison
Open Charts HUMA vs NBTXBanner chart's image
Humacyte
Price$1.09
Change-$0.05 (-4.39%)
Volume$39.91K
Capitalization220.02M
Nanobiotix SA
Price$21.52
Change-$0.01 (-0.05%)
Volume$1K
Capitalization1.02B
HUMA vs NBTX Comparison Chart in %
HUMA
Daily Signal:
Gain/Loss:
NBTX
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
HUMA vs. NBTX commentary
Jan 16, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is HUMA is a Hold and NBTX is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jan 16, 2026
Stock price -- (HUMA: $1.14 vs. NBTX: $21.53)
Brand notoriety: HUMA and NBTX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: HUMA: 71% vs. NBTX: 35%
Market capitalization -- HUMA: $220.02M vs. NBTX: $1.02B
HUMA [@Biotechnology] is valued at $220.02M. NBTX’s [@Biotechnology] market capitalization is $1.02B. The market cap for tickers in the [@Biotechnology] industry ranges from $114.05B to $0. The average market capitalization across the [@Biotechnology] industry is $2.27B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

HUMA’s FA Score shows that 0 FA rating(s) are green whileNBTX’s FA Score has 0 green FA rating(s).

  • HUMA’s FA Score: 0 green, 5 red.
  • NBTX’s FA Score: 0 green, 5 red.
According to our system of comparison, NBTX is a better buy in the long-term than HUMA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

HUMA’s TA Score shows that 4 TA indicator(s) are bullish while NBTX’s TA Score has 5 bullish TA indicator(s).

  • HUMA’s TA Score: 4 bullish, 4 bearish.
  • NBTX’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, NBTX is a better buy in the short-term than HUMA.

Price Growth

HUMA (@Biotechnology) experienced а -5.00% price change this week, while NBTX (@Biotechnology) price change was +0.23% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -0.44%. For the same industry, the average monthly price growth was +2.31%, and the average quarterly price growth was +42.34%.

Reported Earning Dates

HUMA is expected to report earnings on Mar 26, 2026.

NBTX is expected to report earnings on Apr 28, 2026.

Industries' Descriptions

@Biotechnology (-0.44% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NBTX($1.02B) has a higher market cap than HUMA($220M). HUMA YTD gains are higher at: 18.688 vs. NBTX (-6.877).
HUMANBTXHUMA / NBTX
Capitalization220M1.02B22%
EBITDA-18.94MN/A-
Gain YTD18.688-6.877-272%
P/E RatioN/AN/A-
Revenue1.57MN/A-
Total Cash19.5MN/A-
Total Debt29.8MN/A-
TECHNICAL ANALYSIS
Technical Analysis
HUMANBTX
RSI
ODDS (%)
Bullish Trend 2 days ago
85%
N/A
Stochastic
ODDS (%)
Bearish Trend 2 days ago
89%
Bullish Trend 2 days ago
79%
Momentum
ODDS (%)
Bullish Trend 2 days ago
82%
Bearish Trend 2 days ago
86%
MACD
ODDS (%)
Bullish Trend 2 days ago
84%
Bearish Trend 2 days ago
80%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
84%
Bullish Trend 2 days ago
76%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 2 days ago
85%
Advances
ODDS (%)
Bullish Trend 9 days ago
81%
Bullish Trend 2 days ago
76%
Declines
ODDS (%)
Bearish Trend 3 days ago
85%
Bearish Trend 11 days ago
83%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
83%
Bullish Trend 2 days ago
86%
Aroon
ODDS (%)
Bearish Trend 2 days ago
78%
Bullish Trend 2 days ago
85%
View a ticker or compare two or three
Interact to see
Advertisement
HUMA
Daily Signal:
Gain/Loss:
NBTX
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
LSHAX26.100.43
+1.68%
Kinetics Spin-Off and Corp Rest Adv A
FSCIX37.72N/A
N/A
Fidelity Advisor Small Cap I
MSRRX53.53-0.24
-0.45%
MFS Research R2
THCRX32.78-0.15
-0.46%
Thornburg Small/Mid Cap Growth R3
LGOTX34.79-0.31
-0.88%
Lord Abbett Growth Opportunities R5

HUMA and

Correlation & Price change

A.I.dvisor indicates that over the last year, HUMA has been loosely correlated with VKTX. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if HUMA jumps, then VKTX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To HUMA
1D Price
Change %
HUMA100%
+2.70%
VKTX - HUMA
34%
Loosely correlated
+11.89%
RXRX - HUMA
34%
Loosely correlated
+3.41%
AXON - HUMA
32%
Poorly correlated
-1.92%
VCEL - HUMA
31%
Poorly correlated
+0.76%
ACRV - HUMA
31%
Poorly correlated
+7.65%
More

NBTX and

Correlation & Price change

A.I.dvisor tells us that NBTX and XBIO have been poorly correlated (+29% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that NBTX and XBIO's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NBTX
1D Price
Change %
NBTX100%
+0.70%
XBIO - NBTX
29%
Poorly correlated
N/A
HUMA - NBTX
28%
Poorly correlated
+2.70%
CGEN - NBTX
28%
Poorly correlated
+0.51%
OABI - NBTX
28%
Poorly correlated
+0.53%
PBYI - NBTX
28%
Poorly correlated
+2.88%
More